Takeda Pharmaceutical Company Limited Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities
Takeda Pharmaceutical Company Limited (TAK) reported Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities of -JPY 19.67 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities · last filed 2025-06-25
| Period end | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2025-03-31 | -19.67B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | -114.39B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | -32.36B JPY 20-F · filed 2024-06-26 |
| 2022-03-31 | -64.57B JPY 20-F · filed 2023-06-28 |
| 2021-03-31 | 56.25B JPY 20-F · filed 2022-06-29 |
| 2020-03-31 | 3.09B JPY 20-F · filed 2020-06-24 |
| 2019-03-31 | -4.39B JPY 20-F · filed 2020-06-24 |
| 2018-03-31 | -2.23B JPY 20-F · filed 2019-06-27 |